These forward-looking statements include, without limitation, statements regarding the emerging safety profile of our product candidates, including, based on early data, PGN-EDO51, and our plans ...
The funding will be used to continue the clinical development of lead oligonucleotide PGN-EDO51 for DMD, as well as two other oligo drugs PGN-EDODM1 for myotonic dystrophy type 1 (DM1 ...